QVAR pMDI is more cost-effective than fluticasone propionate (FP) or CFC-beclometasone dipropionate (BDP) PMDI in a real-life asthmatic population receiving an increase in ICS dose Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care Year: 2009
Low dose salmeterol/fluticasone propionate combination (SFC) via metered dose inhaler (MDI) improves asthma control and quality of life in patients not well controlled on inhaled steroids (ICS) Source: Eur Respir J 2002; 20: Suppl. 38, 47s Year: 2002
Clinical equivalence of salmeterol/fluticasone propionate combination 50/100mcg b.i.d. delivered via DiskusÔ or CFC-free metered dose Inhaler (MDI) in children with asthma Source: Eur Respir J 2003; 22: Suppl. 45, 311s Year: 2003
Dose linearity of beclometasone dipropionate (BDP) in a pMDI BDP plus formoterol fixed combination Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Non-inferior efficacy of hydrofluoroalkane (HFA) salmeterol (SALM) metered dose inhaler (MDI) compared to salmeterol chlorofluorocarbon (CFC) in adolescent & adult patients with persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 583s Year: 2004
Beclometasone/formoterol administered via extrafine dry powder inhaler in controlled asthmatic patients: Comparison with pMDI and beclometasone monotherapy Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
Efficacy of salmeterol/fluticasone propionate (50/100mcg/day) delivered via the Diskus™ and MDI in children with asthma Source: Eur Respir J 2003; 22: Suppl. 45, 311s Year: 2003
QVAR pMDI is more cost effective than CFC-beclometasone dipropionate (BDP) pMDI in a real-life asthmatic population initiating ICS Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care Year: 2009
A single blinded randomised trial to compare the efficacy and safety of once daily budesonide (400μg) administered by turbuhaler with beclomethasone dipropionate (400μg) given twice daily through a metered-dose inhaler in patients with mild to Source: Eur Respir J 2005; 26: Suppl. 49, 503s Year: 2005
Non-inferiority comparison of budesonide HFA (BUD-HFA) pMDI with budesonide CFC (BUD-CFC) pMDI in patients with persistent moderate asthma Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care Year: 2008
Salmeterol metered dose inhaler (MDI) propelled by hydrofluoroalkane (HFA) is non-inferior to salmeterol chlorofluorocarbon (CFC) propelled MDI in paediatic patients with persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 583s Year: 2004
Synergy with salmeterol and fluticasone propionate after administration from a single inhaler (Seretide™) Source: Eur Respir J 2001; 18: Suppl. 33, 176s Year: 2001
Relative potency of beclomethasone propionate (BDP), delivered by HFA-MDI, and fluticasone propionate (FP) delivered by diskus Source: Eur Respir J 2003; 22: Suppl. 45, 236s Year: 2003
Efficacy of salmeterol/fluticasone propionate combination administered via Diskus inhaler in children with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 429s Year: 2002
Salmeterol/fluticasone propionate in a single inhaler device (SLM/FP) versus theophylline (THEO)+FP in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 386s Year: 2002
Non-inferiority comparison of ipratropium-salbutamol HFA (IB/SAL-HFA) pMDI with ipratropium salbutamol CFC (IF/SAL-CFC) pMDI in patients with COPD Source: Eur Respir J 2007; 30: Suppl. 51, 611s Year: 2007
Comparison of ciclesonide (MDI) once daily and fluticasone propionate (Diskus®) twice daily in the treatment of patients with moderate asthma Source: Eur Respir J 2006; 28: Suppl. 50, 666s Year: 2006
Non-inferiority comparison of formoterol HFA (FM-HFA) pMDI with formoterol CFC (FM-CFC) pMDI in patients with symptomatic asthma Source: Eur Respir J 2007; 30: Suppl. 51, 358s Year: 2007
Acceptability and efficacy of beclomethasone dipropionate (Béclojet HFA®) and fluticasone dipropionate (Flixotide HFA®, FDP) associated with the Volumatic® spacer in adults with mild to moderate persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 473s Year: 2003
Efficacy, safety and cost of budesonide/formoterol in a single inhaler compared with budesonide plus formoterol as separate inhalers Source: Eur Respir J 2002; 20: Suppl. 38, 43s Year: 2002